Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015José Antonio Iribarren, Miguel Ángel von Wichmann, Rafael Rubio et al.|Enfermedades Infecciosas y Microbiología Clínica|2016Cited by 18
Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015José Antonio Iribarren, Miguel Ángel von Wichmann, Rafael Rubio et al.|Enfermedades Infecciosas y Microbiología Clínica|2016Cited by 17
Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavir‐boosted protease inhibitor‐based versus a nonnucleoside reverse transcriptase inhibitor‐based first‐line regimenInmaculada Jarrín, Santiago Moreno, Antonio Antela et al.|HIV Medicine|2014Cited by 7
Switching to Raltegravir in Virologically Suppressed in HIV-1-Infected Patients: A Retrospective, Multicenter, Descriptive StudyDaniel Podzamczer, The TORAL Study Group, Estebán Martínez et al.|Current HIV Research|2012Cited by 3